P I Industries Q2FY26: Revenues Drop 16%, Pharma Up 104% — Agro Giant’s Identity Crisis or Diversification Masterstroke?
1. At a Glance
Welcome to P I Industries Ltd, the agrochemical czar that’s suddenly catching biotech fever. The company — India’s poster child for custom synthesis and contract manufacturing (CSM) in agrochemicals — posted Q2FY26 revenue of ₹1,872 crore, down 16% YoY, while PAT stood at ₹409 crore, down 19.5% YoY. For H1FY26, revenue clocked ₹3,772.8 crore and profit ₹809.3 crore.
But wait — the pharma division decided to show off, growing +104%, proving that at least one child in this family listens to growth advice. With a market cap of ₹56,288 crore, ROCE of 22.9%, and ROE of 17.6%, PI remains an investor’s chemical romance, albeit with a hint of midlife crisis.
Stock’s P/E stands at 37.2, higher than industry’s 28.6, because apparently “premium” means “please ignore the drop in profit.” Debt? A negligible ₹242 crore. Dividend yield? A modest 0.43%, like a polite cough after dinner.
The scrip trades at ₹3,710 (down 1.88% as of Nov 12, 2025) — off its ₹4,553 high but still flexing that chemical confidence. Sales growth dropped -5.9%, and profits dipped -14.8%, but with R&D spending of ~3% of revenue and 210+ patents, it’s clear PI prefers innovation over inflation.
So, is this an agrochemical empire morphing into a biotech beauty — or just a bored veteran trying new hobbies? Let’s find out.
2. Introduction
If Indian chemical companies were Bollywood actors, P I Industries would be the Aamir Khan of agrochemicals — perfectionist, diversified, and occasionally overthinking its roles. Born in the dusty fields of Udaipur but now running labs from Jaipur to Seattle, PI has quietly become India’s most sophisticated chemistry lab that also happens to make stuff that kills bugs.
But FY25 and H1FY26 haven’t been smooth. Global agrochemical demand slumped, inventory corrections hit everyone from UPL to Bayer, and crop prices danced like an unstable rupee. Yet, PI didn’t just sit back — it went full “Breaking Bad meets Biotech.”
It spent nearly ₹928 crore in FY25 on capex, launched 13 new products, and even acquired Plant Health Care Plc in the UK for £32.8 million to enter the agricultural biologicals space. You know, those fancy protein-peptide technologies that make crops grow faster and guilt-free.
Still, with export sales down and margins under pressure, investors are whispering: “Has PI peaked?” The company, meanwhile, is busy commissioning kilo-scale pharma facilities in Italy and dropping phrases like “Electronic Chemicals” and “Biologicals” like buzzword confetti.
The duality is real — agro by roots, pharma by ambition. But can it juggle both? Grab your lab coats, because this balance sheet smells like fertilizer and future money.
3. Business Model – WTF Do They Even Do?
Imagine a chemistry student who started by making pesticides and then became obsessed with making everything that reacts with something. That’s P I Industries.
Two main segments run the show:
Agro Chemicals (97% of FY25 revenue) The kingpin segment. It’s split into:
CSM Exports: Where PI plays Breaking Bad for global agro giants — synthesizing secret molecules in shiny reactors. They handle everything from process development to pilot scale-up, then mass production. In short: “You design it, we cook it.”
Domestic Agri Brands: The desi portfolio featuring insecticides, fungicides, and herbicides for crops like rice, cotton, corn, wheat, and chilli. You name the crop, they’ve got something to spray on it.
Fun fact: PI is India’s largest producer of Profenofos, Ethion, and Phorate — basically, the Avengers of Indian farmlands.
Pharma (3% of FY25 revenue) The new kid in the lab coat. Born from the acquisition of Therachem Research Medilab LLC and Archimica SpA in 2023 for ₹775 crore, this division now handles contract development and manufacturing (CDMO) for pharma intermediates. Pharma revenue grew 6% of total export growth in FY25 and is expected to triple by FY28. So yes, PI’s trying to cook APIs while still killing pests.
Global reach? 40+ countries, 8 manufacturing sites, and offices from India to the Netherlands. If chemistry were a religion, PI is already evangelizing globally.
I think you haven’t addressed the elephant in the room – dependency on Pyraxosulphane. With the molecule going off patent in the US, how does it impact PIIND topline and bottomline growth?
One Response
I think you haven’t addressed the elephant in the room – dependency on Pyraxosulphane. With the molecule going off patent in the US, how does it impact PIIND topline and bottomline growth?